Details

Autor(en) / Beteiligte

• Tsukahara, Tomohide
• Watanabe, Kazue
• Murata, Kenji
• Takahashi, Akari
• Mizushima, Emi
• Shibayama, Yuji
• Kameshima, Hidekazu
• Hatae, Ryo
• Ohno, Yasuo
• Kawahara, Rituko
• Murai, Aiko
• Nakatsugawa, Munehide
• Kubo, Terufumi
• Kanaseki, Takayuki
• Hirohashi, Yoshihiko
• Terui, Takeshi
• Asanuma, Hiroko
• Hasegawa, Tadashi
• Sato, Noriyuki
• Torigoe, Toshihiko

Titel

Peptide vaccinations elicited strong immune responses that were reboosted by anti-PD1 therapy in a patient with myxofibrosarcoma

Ist Teil von

• Cancer Immunology, Immunotherapy, 2020-02, Vol.69 (2), p.189-197

Ort / Verlag

Berlin/Heidelberg: Springer Berlin Heidelberg

Erscheinungsjahr

2020

Quelle

MEDLINE

Beschreibungen/Notizen

• Peptide-based immunotherapy does not usually elicit strong immunological and clinical responses in patients with end-stage cancer, including sarcoma. Here we report a myxofibrosarcoma patient who showed a strong clinical response to peptide vaccinations and whose immune responses were reboosted by anti-PD1 therapy combined with peptide vaccinations. The 46-year-old man showed a strong response to the peptide vaccinations (papillomavirus binding factor peptide, survivin-2B peptide, incomplete Freund’s adjuvant, and polyethylene glycol-conjugated interferon-alpha 2a) and subsequent wide necrosis and massive infiltration of CD8+ T cells in a recurrent tumor. The patient’s immune responses weakened after surgical resection; however, they were reboosted following the administration of nivolumab combined with peptide vaccinations. Thus, anti-PD1 therapy combined with peptide vaccinations might be beneficial, as suggested by the observations in this sarcoma patient.